Q1 2022 13F Holders as of 3/31/2022
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
47.9M
-
Number of holders
-
222
-
Total 13F shares, excl. options
-
51.2M
-
Shares change
-
+1.55M
-
Total reported value, excl. options
-
$3.24B
-
Value change
-
+$122M
-
Put/Call ratio
-
0.55
-
Number of buys
-
112
-
Number of sells
-
-117
-
Price
-
$63.22
Significant Holders of HAEMONETICS CORP - Common Stock (HAE) as of Q1 2022
273 filings reported holding HAE - HAEMONETICS CORP - Common Stock as of Q1 2022.
HAEMONETICS CORP - Common Stock (HAE) has 222 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 51.2M shares
.
Largest 10 shareholders include WELLINGTON MANAGEMENT GROUP LLP (6.17M shares), BlackRock Inc. (5.95M shares), Capital Research Global Investors (5.45M shares), VANGUARD GROUP INC (4.91M shares), Neuberger Berman Group LLC (3.77M shares), STATE STREET CORP (1.73M shares), FRANKLIN RESOURCES INC (1.47M shares), Fisher Asset Management, LLC (1.19M shares), LONDON CO OF VIRGINIA (971K shares), and LGT CAPITAL PARTNERS LTD. (966K shares).
This table shows the top 222 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.